Quarterly ResultMay 7, 2026, 04:19 PM
Xeris Biopharma Q1 Net Income $2.23M; Revenue +38.3% to $83.13M
AI Summary
Xeris Biopharma Holdings, Inc. reported a significant financial turnaround for the first quarter of 2026, achieving a net income of $2.23 million compared to a net loss of $9.22 million in the prior year. Total revenue increased by 38.3% to $83.13 million, driven primarily by strong growth in Recorlev sales. The company also generated positive cash flow from operating activities, a substantial improvement from the previous year's cash burn. Basic net income per common share was $0.01.
Key Highlights
- Net income of $2.23 million, a significant improvement from a $9.22 million net loss in Q1 2025.
- Total revenue increased 38.3% to $83.13 million, up from $60.12 million year-over-year.
- Product revenue grew to $82.45 million from $57.80 million in Q1 2025.
- Recorlev product revenue surged 94.9% to $49.77 million from $25.53 million in Q1 2025.
- Generated $9.87 million in net cash from operating activities, reversing a $10.03 million outflow.
- Basic net income per common share was $0.01, compared to a loss of $0.06 in Q1 2025.
- Cash and cash equivalents stood at $111.75 million as of March 31, 2026.
- Issued 2.28 million common shares for $7.3 million from warrant settlements in January 2026.
Price Impact
More from XERS